Core Viewpoint - The article highlights the alarming increase in diabetes prevalence in China, emphasizing its significant impact on mortality and life expectancy, particularly among specific demographics such as rural populations and younger individuals [5][8][12]. Summary by Sections Diabetes Prevalence and Impact - Diabetes incidence in China surged 17 times from 0.7% in 1980 to 12.4% in 2018, with over 140 million adult patients by 2021, projected to reach 174 million by 2045 [5]. - The proportion of prediabetic individuals has reached 38.1%, indicating a growing public health concern [5]. Mortality Risks Associated with Diabetes - A study published in "Diabetes Care" revealed that diabetes patients face a 61% higher risk of all-cause mortality and a 59% increased risk of death from cardiovascular diseases (CVD) compared to those with normal blood sugar levels [6][8]. - Even prediabetic individuals experience an 8% and 10% increase in all-cause and CVD mortality risks, respectively [6]. Life Expectancy Reduction - Diagnosis of diabetes at age 40 can reduce life expectancy by approximately 4.2 years for women and 4.3 years for men [8]. - Prediabetic individuals also face a reduction in life expectancy, averaging 0.7 years for those diagnosed at 40 [8]. Cardiovascular Disease Risks - Diabetes patients have a 59% increased risk of death from CVD, with rural patients facing a 75% higher risk compared to urban counterparts [12]. - Younger patients (under 65) are at a higher risk of CVD-related mortality than older patients, with a 89% increase compared to 42% for older groups [12]. Cancer and Other Health Risks - Diabetes patients show a 31% higher overall cancer mortality rate, with specific increases of 40% for lung cancer and 134% for liver cancer [13][14]. - The study emphasizes the need for targeted prevention strategies, especially in rural areas and among younger populations [14]. Recommendations for Action - Establishing a diabetes-CVD prevention and control system in rural areas is crucial [14]. - Clinical treatments should consider the patient's location and age to enhance effectiveness [14]. - There is a strong call for increased public awareness and early screening for blood sugar abnormalities to mitigate health risks [14].

Group 1 - Astaxanthin, derived from Haematococcus pluvialis, is recognized as one of the strongest natural antioxidants and has garnered significant attention for its health benefits [1] - Research conducted by a team from Xiamen Health Medical Big Data Center indicates that astaxanthin can improve insulin resistance in type 2 diabetes mellitus (T2DM) through various mechanisms [3][4] - The study highlights that astaxanthin lowers fasting blood glucose levels and enhances insulin sensitivity while reducing inflammation by inhibiting TNF-α and IL-6 expression [3][5] Group 2 - The market for astaxanthin is experiencing robust growth, driven by multiple studies confirming its health benefits, particularly in diabetes management [7] - Green A Bio, a pioneer in the industrialization of Haematococcus pluvialis astaxanthin in China, has achieved significant breakthroughs in astaxanthin production technology and holds patents in this field [7] - The company has launched a range of high-quality products, including Red A Astaxanthin and Frozen Age Astaxanthin, which support various health benefits such as antioxidant effects, anti-inflammatory properties, and improved glucose metabolism [7] Group 3 - Diabetes, characterized by high blood sugar levels, is a chronic metabolic disease with increasing prevalence [8] - The potential of astaxanthin in diabetes prevention and treatment is becoming more evident as scientific research progresses [8] - There is optimism that astaxanthin will play a significant role in various health domains, contributing to human health advancements [8]

罗氏制药中东地区负责人奥法特·贝罗；信诺医疗保健中东和非洲（不含沙特）首席执行官利亚·科特里尔；以及 January AI公司创始人兼首席执行官诺辛·哈希米（从左到右）。 图片来源：Iman Al-dabbagh—Fortune 据预测，到本世纪中叶，全球糖尿病患者将达13亿人，若计入糖尿病前期人群，这一数字将攀升至50 亿。当前，人工智能技术能够帮助糖尿病患者实时掌握食物成分及潜在血糖反应；未来，人工智能还将 助力预测患者可能罹患的病症，并指导采取早期干预措施。 在利雅得召开的《财富》"全球最具影响力商界女性"峰会上，医疗行业领袖们指出，人工智能将在防治 糖尿病相关疾病方面扮演日益重要的角色，尤其是存在大量生活方式相关糖尿病患者的中东等地区。 人工智能健康平台January AI创始人兼首席执行官诺辛·哈希米指出："数据触目惊心。至2050年，全球 糖尿病患者将达到13亿，而糖尿病前期人群规模约为这个数字的三倍。……这意味着超50亿人将出现胰 岛素抵抗，占全球半数人口。"该平台通过人工智能技术提供个性化营养建议与血糖监测分析。 信诺医疗保健（Cigna Healthcare）中东及非洲（不含沙特）首席执行官 ...